Cullinan Therapeutics Inc (NAS:CGEM)
$ 17 0.82 (5.07%) Market Cap: 979.78 Mil Enterprise Value: 502.68 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 30/100

Cullinan Oncology Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 06:30PM GMT
Release Date Price: $10.41 (-4.50%)
Raji Gunasekera
J.P. Morgan Securities LLC - Analyst

Hi. Good morning. Welcome to the JPMorgan Healthcare Conference. I know it's final stretch on a Thursday, so really appreciate you all being here. My name is Raji Gunasekera with the healthcare investment banking team at JPM. Today, I'm pleased to introduce the team from Cullinan oncology, and we have their CEO, Nadim Ahmed. I'll hand it over to you.

Nadim Ahmed Cullinan Oncology
Inc. - President & CEO

Thank you very much. It's a pleasure to be here to share all of the exciting developments going on at Cullinan Oncology. Next slide is my disclaimer slide.

At Cullinan Oncology, we take a very unique approach to developing first-in-class and best-in-class programs through what we call our modality-agnostic targeted oncology approach. What that means is that the start of our discovery process, we identify a high-impact cancer targets, and it's only then that we think about the best vehicle to prosecute against those targets. So for us, it's always target, first; modality, second, rather than the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot